338 related articles for article (PubMed ID: 29631035)
1. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer.
Ostios-Garcia L; Faig J; Leonardi GC; Adeni AE; Subegdjo SJ; Lydon CA; Rangachari D; Huberman MS; Sehgal K; Shea M; VanderLaan PA; Cheng MP; Marty FM; Hammond SP; Costa DB; Awad MM
J Thorac Oncol; 2018 Jul; 13(7):1037-1042. PubMed ID: 29631035
[TBL] [Abstract][Full Text] [Related]
2. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes.
Chae YK; Chiec L; Mohindra N; Gentzler R; Patel J; Giles F
Cancer Immunol Immunother; 2017 Jan; 66(1):25-32. PubMed ID: 27761609
[TBL] [Abstract][Full Text] [Related]
3. Clinical Experience of External Application of Clearing Heat and Removing Dampness in Relieving Grade 2 to 3 Rash Caused by Programed Cell Death Protein 1 (PD-1)/Programed Cell Death Ligand 1 (PD-L1) Inhibitors: A Single-Center Retrospective Study.
Chen SY; Zhao FM; Yu R; Sun L; Yin YD; Zhang GC; Yang JY; Shu QJ
Integr Cancer Ther; 2024; 23():15347354231226108. PubMed ID: 38240227
[TBL] [Abstract][Full Text] [Related]
4. [Pembrolizumab in adjuvant therapy in non-small cell lung cancers].
Lefèvre A; Tissot C
Bull Cancer; 2024 Apr; 111(4):334-336. PubMed ID: 38471995
[No Abstract] [Full Text] [Related]
5. Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment.
Frega S; Ferro A; Bonanno L; Guarneri V; Conte P; Pasello G
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111093
[No Abstract] [Full Text] [Related]
6. Safety and efficacy of PD-1 inhibitors in HIV-infected patients with severe comorbidities: a prospective observational cohort study.
Zhu X; Liu X; Wan Z; Hui J; Tao R; Peng X; Su J; Huang Y; Zhu B
Chin Med J (Engl); 2023 Nov; 136(22):2750-2752. PubMed ID: 37882105
[No Abstract] [Full Text] [Related]
7. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression testing in non-small cell lung cancer.
Teixidó C; Vilariño N; Reyes R; Reguart N
Ther Adv Med Oncol; 2018; 10():1758835918763493. PubMed ID: 29662547
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Forde PM; Chaft JE; Smith KN; Anagnostou V; Cottrell TR; Hellmann MD; Zahurak M; Yang SC; Jones DR; Broderick S; Battafarano RJ; Velez MJ; Rekhtman N; Olah Z; Naidoo J; Marrone KA; Verde F; Guo H; Zhang J; Caushi JX; Chan HY; Sidhom JW; Scharpf RB; White J; Gabrielson E; Wang H; Rosner GL; Rusch V; Wolchok JD; Merghoub T; Taube JM; Velculescu VE; Topalian SL; Brahmer JR; Pardoll DM
N Engl J Med; 2018 May; 378(21):1976-1986. PubMed ID: 29658848
[TBL] [Abstract][Full Text] [Related]
11. Blockade of Tumor-Expressed PD-1 promotes lung cancer growth.
Du S; McCall N; Park K; Guan Q; Fontina P; Ertel A; Zhan T; Dicker AP; Lu B
Oncoimmunology; 2018; 7(4):e1408747. PubMed ID: 29632720
[TBL] [Abstract][Full Text] [Related]
12. A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer.
You W; Liu M; Miao JD; Liao YQ; Song YB; Cai DK; Gao Y; Peng H
J Cancer; 2018; 9(7):1200-1206. PubMed ID: 29675101
[No Abstract] [Full Text] [Related]
13. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Hellmann MD; Nathanson T; Rizvi H; Creelan BC; Sanchez-Vega F; Ahuja A; Ni A; Novik JB; Mangarin LMB; Abu-Akeel M; Liu C; Sauter JL; Rekhtman N; Chang E; Callahan MK; Chaft JE; Voss MH; Tenet M; Li XM; Covello K; Renninger A; Vitazka P; Geese WJ; Borghaei H; Rudin CM; Antonia SJ; Swanton C; Hammerbacher J; Merghoub T; McGranahan N; Snyder A; Wolchok JD
Cancer Cell; 2018 May; 33(5):843-852.e4. PubMed ID: 29657128
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Hellmann MD; Ciuleanu TE; Pluzanski A; Lee JS; Otterson GA; Audigier-Valette C; Minenza E; Linardou H; Burgers S; Salman P; Borghaei H; Ramalingam SS; Brahmer J; Reck M; O'Byrne KJ; Geese WJ; Green G; Chang H; Szustakowski J; Bhagavatheeswaran P; Healey D; Fu Y; Nathan F; Paz-Ares L
N Engl J Med; 2018 May; 378(22):2093-2104. PubMed ID: 29658845
[TBL] [Abstract][Full Text] [Related]
15. Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab.
Dumenil C; Massiani MA; Dumoulin J; Giraud V; Labrune S; Chinet T; Giroux Leprieur E
PLoS One; 2018; 13(4):e0195945. PubMed ID: 29684049
[TBL] [Abstract][Full Text] [Related]
16. Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel.
Russo A; Franchina T; Ricciardi GRR; Battaglia A; Scimone A; Berenato R; Giordano A; Adamo V
J Cell Physiol; 2018 Oct; 233(10):6337-6343. PubMed ID: 29672849
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
Lung Cancer; 2018 May; 119():14-20. PubMed ID: 29656747
[TBL] [Abstract][Full Text] [Related]
18. Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases.
Schapira E; Hubbeling H; Yeap BY; Mehan WA; Shaw AT; Oh K; Gainor JF; Shih HA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):624-629. PubMed ID: 29678530
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report.
Owada-Ozaki Y; Muto S; Takagi H; Inoue T; Watanabe Y; Fukuhara M; Yamaura T; Okabe N; Matsumura Y; Hasegawa T; Ohsugi J; Hoshino M; Shio Y; Nanamiya H; Imai JI; Isogai T; Watanabe S; Suzuki H
J Thorac Oncol; 2018 Aug; 13(8):1217-1221. PubMed ID: 29654927
[TBL] [Abstract][Full Text] [Related]
20. Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy.
Parakh S; Cebon J; Klein O
Oncologist; 2018 Jul; 23(7):849-851. PubMed ID: 29666298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
